Coninstarz,
You have done an amazing job with IHUB. I want to thank you fo all your hard work continually providing up-to-date info and balanced view to other INSM investors.
Your info regarding S-3 filing is very useful and keeps things in perspective.
I agree with everyone that at 2.3 PPS (market cap of about 100-150 mil), INSM is a bargain. The greatest risk to company, FDA and orphan drug approval, has passed and thus INSM is in the best shape that it could have hoped for- yet the comany has not been rewarded with a higher PPS. As noted by others, new risks and new challenges remain- however, these challenges and risks are minor compared to the initial risk of FDA approval- lack of approval would have been devastating to the company. Iplex approval was crucial in that it not only proves that Iplex is not only clinically useful (and superior to increlex), but allows INSM to generate revenue to support other more promising clinical trials. If Iplex indeed achieves sales of 100-200 million dollar per year, this should be sufficient to allow INSM to proceed with clinical trials without worrying about new funding.
I think the biggest potential positives for the near future are 1) announcement of pricing of Iplex (I personally believe, it will be priced over 22,000 per year- my guess is between 23-25K), 2) announcement of distribution and marketing infoplans ( possibly with new partners) and 3) info as to when Iplex will hit the market (it would be very important for Iplex to hit the market in 2nd quarter- if not this will be very negative). In the meantime there will be great deal of up and down movement of this stock with recent infusion of day traders.
IMO, the biggest near-term risk is the market penetration of the drug. The S-3 filing has addressed other important concern regarding financing. Although it has been perceived by many that S-3 filing is a negative- acquiring more fund for an emerging biotech comapny is never a bad thing IMO.
Good luck to all INSM investors.
